BioSpace News Archive

Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced that it will publish financial results for the second quarter 2021 and provide a business update on August 12, 2021.

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a discussion at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 9:00 a.m. ET.

Concert Pharmaceuticals, Inc. reported financial results for the second quarter of 2021.

Virios Therapeutics, Inc., a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced that its second quarter 2021 financial results will be reported on Thursday, August 12, 2021 before the open of the financial markets.

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, announced financial results for the second quarter and first six months ended June 30, 2021, and recent highlights.

Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced the nomination of EDP-235, its lead oral protease inhibitor specifically designed for the treatment of COVID-19.

Takeda Pharmaceutical Company Limited announced the publication of the final results from the Phase 3 HELP Study™ Open-label Extension designed to evaluate the long-term safety and efficacy of TAKHZYRO® 300mg every two weeks for up to 2.5 years.

Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced data presentations on two of its skin cancer gene expression profile tests at the DEF Essential Resource Meeting NP/PA CME Conference, taking place from Aug. 5-8, 2021.

Sierra Oncology, Inc. granted stock options to three new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

Wave Life Sciences Ltd. today announced financial results for the second quarter ended June 30, 2021 and provided a business update.